Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Melanoma × rubitecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 3 Stomach Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Leiomyosarcoma 1 Gastrointestinal Stromal Tumors 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

aldesleukin 61 Cyclophosphamide 43 fludarabine phosphate 28 fludarabine 27 Interleukin-2 22 incomplete Freund's adjuvant 21 Ipilimumab 15 Specimen Handling 13 Magnetic Resonance Spectroscopy 12 MART-1 Antigen 12 CTLA-4 Antigen 12 sargramostim 11 montanide ISA 51 11 Biopsy 11 Sorafenib 10 Filgrastim 10 Nivolumab 9 pembrolizumab 8 Interferon-alpha 8 trametinib 7 dabrafenib 7 Sirolimus 7 Bevacizumab 7 temsirolimus 6 Temozolomide 5 Introns 5 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5 cediranib 4 cabozantinib 4 Whole-Body Irradiation 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00005875 2013-12-04

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡